ICER crit­i­cizes cost of 8 tar­get­ed im­mune mod­u­la­tors for UC, rec­om­mend­ing some deep dis­counts

While 8 tar­get­ed im­mune mod­u­la­tors (TIMs) on the mar­ket for ul­cer­a­tive col­i­tis have proved ben­e­fi­cial to pa­tients, non­prof­it cost-ef­fec­tive­ness watch­dog ICER called the drugs un­rea­son­ably ex­pen­sive, rec­om­mend­ing some deep dis­counts to match the drugs with their ac­tu­al val­ue.

In a re­port re­leased Fri­day, ICER as­sessed the cost vs. clin­i­cal ben­e­fit of mar­ket leader Hu­mi­ra — for which Ab­b­Vie has faced price goug­ing ac­cu­sa­tions — as well as Janssen’s Sim­poni, Ste­lara and Rem­i­cade, Mer­ck’s Ren­flex­is, Pfiz­er’s In­flec­tra and Xel­janz, and Take­da’s En­tyvio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER